Financial Review: Coeptis Therapeutics (ZSQR) & Its Competitors

Coeptis Therapeutics (NASDAQ:ZSQR) is one of 953 publicly-traded companies in the “Software” industry, but how does it contrast to its competitors? We will compare Coeptis Therapeutics to similar businesses based on the strength of its analyst recommendations, profitability, earnings, risk, dividends, valuation and institutional ownership.

Earnings and Valuation

This table compares Coeptis Therapeutics and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Coeptis Therapeutics	N/A	-$11.92 million	-2.06
Coeptis Therapeutics Competitors	$1.79 billion	$385.91 million	106.60

Coeptis Therapeutics’ competitors have higher revenue and earnings than Coeptis Therapeutics. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

13.9% of Coeptis Therapeutics shares are held by institutional investors. Comparatively, 41.8% of shares of all “Software” companies are held by institutional investors. 24.2% of Coeptis Therapeutics shares are held by insiders. Comparatively, 19.9% of shares of all “Software” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

Coeptis Therapeutics has a beta of -0.29, meaning that its share price is 129% less volatile than the S&P 500. Comparatively, Coeptis Therapeutics’ competitors have a beta of 1.34, meaning that their average share price is 34% more volatile than the S&P 500.

Profitability

This table compares Coeptis Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Coeptis Therapeutics	-773.72%	-49.45%	-46.88%
Coeptis Therapeutics Competitors	-612.64%	20.88%	-8.99%

Analyst Recommendations

This is a breakdown of recent ratings for Coeptis Therapeutics and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coeptis Therapeutics	1	0	0	0	1.00
Coeptis Therapeutics Competitors	5746	21522	44878	1496	2.57

As a group, “Software” companies have a potential upside of 28.86%. Given Coeptis Therapeutics’ competitors stronger consensus rating and higher possible upside, analysts plainly believe Coeptis Therapeutics has less favorable growth aspects than its competitors.

Summary

Coeptis Therapeutics competitors beat Coeptis Therapeutics on 12 of the 13 factors compared.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.